Avadel Pharmaceuticals plc

– 12 accepted abstracts highlight Company’s emerging leadership in narcolepsy – – Data adds to growing body of evidence demonstrating positive clinical benefit and patient preference of…

<!-- Name:DistributionId Value:8829171 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

<!-- Name:DistributionId Value:8798190 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

- Delisting of REMS Patent sets path to potentially accelerate final approval by FDA DUBLIN, Ireland, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a…

- Results identify mood, sleep and pain disorders as the most common comorbidities in people living with narcolepsy - - Encore presentations at ANA 2022 reinforce positive data from…

Discrete choice experiment demonstrated that number of doses was the most important attribute driving patient and clinician preference for oxybate therapy, with once-nightly dosing strongly…

DUBLIN, Ireland, March 10, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg…

DUBLIN, Ireland, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that the U.S.…